LATEST ALERTS
CBD-Intel’s crystal ball reveals possible intoxicating prospects for the year ahead
29th December 2021 - News analysis |
“Intoxicating” will be the word to watch for and THC will be the main driver for developments in 2022, CBD-Intel predicts
Health and science
So it’s farewell to 2021 – a year that promised little and delivered less
27th December 2021 - News analysis |
If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype. As predicted, there was little movement in many of the major issues controlling the CBD market
Intoxicating hemp products in the US – opportunity or risk?
20th December 2021 - Regulatory reports |
Some sellers of intoxicating cannabinoid products claim legality under the 2018 US Farm Bill. CBD-Intel believes that many hemp-derived cannabinoids do not violate federal controlled substance law
UK health trust teams up with Awakn to investigate psychedelic treatment
13th December 2021 - News analysis |
The UK’s National Health Service (NHS) has expressed some interest in the viability of psychedelics as a course of treatment
Podcast: A UK doctor’s take on CBD
25th November 2021 - Podcasts |
CBD-Intel podcast editor Jon Bruford meets Dr K CBD’s Dr Ruchira Karunadasa who explains why he believes the company has an important role to play in helping the industry towards mature dialogue, and the impact that
Gupta’s appointment and nomination of Califf may indicate change in US climate
16th November 2021 - News analysis |
Rahul Gupta has been confirmed by the US Senate as director of National Drug Control Policy, while president Joe Biden intends to nominate Robert Califf as head of the US Food and Drug Administration (FDA)
Two studies seek to show the benefits of cannabinoids for liver health
5th November 2021 - News analysis |
A research team at the University Medical Center Groningen (UMCG) in the Netherlands recently launched a three-year study into whether medicinal cannabis oil can help to regress liver-cancer tumours
Concerns arise as Italian study finds pesticides and metals in hemp flowers
29th October 2021 - News analysis |
Another study, this time from Italy, has found potentially dangerous levels of heavy metals and pesticides in CBD products. Researchers were worried by the results and asked regulators and legislators to act
Brazilian report highlights theoretical growth but small current numbers
22nd October 2021 - News analysis |
Interest in the Brazilian medical cannabinoid market is based on optimistic projections of growth continuing in the same vein rather than concrete current numbers, a domestic report has confirmed
Potential for psychedelic treatments prompts big North American buyouts
15th October 2021 - News analysis |
Interest in psychedelic drugs and treatments continues to grow, as evidenced by three major takeovers in Canada and the USA, two involving drug treatments developments and another offering a network of ketamine infusion treatment centres
Charlotte’s Web new dietary ingredient application did include ValidCare data
14th October 2021 - Blogs , News analysis |
It turns out the Charlotte’s Web application to the US FDA for the registration of a full spectrum hemp extract as a new dietary ingredient (NDI) DID include data from the ValidCare industry study
Personal mental health histories lead to investments in psychedelics research
12th October 2021 - News analysis |
Two North American entrepreneurs have put millions of dollars into exploring the treatment efficacy of psychedelics, based on personal experience of using them to help deal with their own mental health issues
German medical cannabis imports rise but no sign of domestic production yet
8th October 2021 - News analysis |
German imports of medical cannabis flowers rose by 80% in the first half of 2021 compared to the same period of 2021, but hopes of establishing local production were dashed
US DEA calls for big increases in cannabis and psilocybin production for research
23rd September 2021 - News analysis |
The US Drug Enforcement Agency (DEA) is calling for an increase in production of cannabis and psychedelics to supply federal research and clinical trials
NFL vet claims orange-peel CBD ‘purer’ than cannabis or hemp-derived products
13th September 2021 - News analysis |
NFL veteran Chris Hetherington has launched a CBD oil derived entirely from orange peel, describing it as “crystalline CBD at a purity and consistency difficult to match with cannabis or hemp-derived material”
Horse sense or dog trial? The science and law behind CBD petcare products
1st September 2021 - News analysis |
CBD pet products remain in a grey area in terms of both legality and effectiveness – but there have been some attempts in both to shed light into the darkness
The entourage effect: new studies could help to explain the phenomenon
18th August 2021 - News analysis |
Two new studies on the biochemistry of cannabinoids could provide answers to a puzzling question – how does the entourage effect work?
Medical use of psilocibyn in Canada could grow, but consumer sale unlikely
13th August 2021 - News analysis |
A court case could force the Canadian government to process requests to use psilocybin for psychotherapeutic treatment more quickly
Testing the testers: UK and US CBD testing labs go under the microscope
13th August 2021 - News analysis |
A recent ring trial assessment of the lab performances and methods for measuring CBD in commercial products has given some good news to the industry
What lies behind the CBD industry’s continued interest in the field of nicotine replacement?
11th August 2021 - Blogs , News analysis |
A new study has shown some limited effectiveness for the use of CBD in combatting nicotine withdrawal symptoms
Test-tube cannabinoids: scientists seek alternatives to agricultural production
11th August 2021 - News analysis |
New methods for laboratory production of cannabinoids show some promise – but it’s still not clear whether they will yield enough to be commercially viable
Study raises early hopes for the use of CBD in treating nicotine withdrawal
5th August 2021 - News analysis |
Researchers at the University of San Diego in California have published a paper showing early evidence that CBD may help ease the symptoms of nicotine withdrawal
Public health insurance is driving growth of the German medical cannabis market
3rd August 2021 - News analysis |
Public health insurance reimbursements and no defined list of indications for medical cannabis have helped the German medical cannabis market start to realise its massive potential
Watchdog study finds high levels of inaccuracy in delta-8 THC labels
28th July 2021 - News analysis |
Research from a CBD watchdog firm has found considerable inconsistencies between the levels of delta-8 THC stated on product labels and what was revealed by laboratory tests
Researchers find even synthetic CBD can degrade and produce THC if badly stored
26th July 2021 - News analysis |
Both synthetic and plant-derived CBD degrade when stored incorrectly, producing THC, according to a new study
Company behind the UK’s first medical cannabis vape aims to lead a revolution
22nd July 2021 - News analysis |
London-listed Kanabo has launched the first medical cannabis vaping product in the UK in a move the company’s founder hopes will ultimately revolutionise the way medicines are administered
Javid appointment as UK health minister raises slight hope for medical cannabis
19th July 2021 - News analysis |
Medical cannabis advocates are keen to see if Sajid Javid’s appointment as UK health secretary means he will continue his work from 2018, when he helped change the law on medicinal cannabis prescriptions
Clinical trials to explore potential of psychedelics are on the rise in Europe
16th July 2021 - News analysis |
A range of European firms are looking to further advance research into psychedelic compounds after securing funding and backing
A long process – Europe’s still asking questions about novel food submission
14th July 2021 - News analysis |
A year and eight months after Cibdol submitted its novel food application for EU authorisation of synthetically produced CBD, the Swiss company is still fielding questions from the European Food Safety Authority (ESFA)
More minor cannabinoids – could THCP and CBDP offer an interesting side dish?
1st July 2021 - News analysis |
What are the potential implications for the cannabinoids market of two recently discovered compounds with chemical structures similar to those of CBD and THC – and what are they and their potential effects anyway?
Freeing the ‘green pig’ – moves afoot to press France to legalise cannabis
29th June 2021 - News analysis |
France is lagging behind its neighbours on medical cannabis – the potential “green pig” of French agriculture – according to an author of a report which called for it to be legalised on health and finance grounds
Podcast: Hemp growing challenges in the UK
29th June 2021 - Podcasts |
CBD-Intel podcast editor Jon Bruford discusses the situation of medical cannabis and the challenges of hemp-growing in the UK with Dr Callie Seaman, research director at Aqualabs Ltd
Combining other topical ingredients with cannabinoids goes more than skin-deep
16th June 2021 - News analysis |
Trends such as sustainability and organic plant-based ingredients are helping to drive the market for hemp and cannabinoid topical products even higher, with combination products all the rage
Initial results from Project Twenty21 reveal promise – and a few caveats
26th May 2021 - News analysis |
CBD-Intel assesses how Project Twenty21 is faring as it seeks to construct a registry of medical cannabis users in the UK and Europe, providing real world data on potential efficacy
Cannabinoids, cannabis and pain: a promising area for further research
13th May 2021 - News analysis |
Pain is a familiar part of everybody’s life, yet it remains a remarkably hard subject to study. It therefore is unsurprising that studies have come to differing conclusions on the use of cannabis and cannabinoids for pain relief
Minor cannabinoids: what are they, and how could they be of benefit?
28th April 2021 - News analysis , Resources |
CBD-Intel offers a review of the science behind some of cannabis’s lesser-known compounds – the so-called “minor cannabinoids” – with an emphasis on their potential applications
Reasons for CBD use are increasing and diversifying in the UK
27th April 2021 - News analysis , Resources |
In comparison with our 2019 consumer survey results, the reasons given for using CBD have changed and diversified
CBD and Covid-19 – lab experiments show promise, but don’t hold your breath
21st April 2021 - News analysis |
Early research into the possibility of CBD having a role to play in the fight against coronavirus infections has shown some initial promise. Any practical application remains a long way off, however
Cann Group teams up with Emyria to develop pharmacy grade CBD capsules
21st April 2021 - News analysis |
Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria
The next big thing – or are investors in psychedelics playing the long game?
19th April 2021 - News analysis |
While legal cannabis is still a relatively new industry, investors are already looking for the next sector to boom – and many think that will be psychedelics
Tilray expands its influence Down Under, moving on New Zealand medical market
15th April 2021 - News analysis |
Canadian cannabis firm Tilray is moving in on New Zealand’s market for medical cannabis and has received the necessary approvals to launch Tilray medical cannabis products across the country
How cannabis derivatives could help to preserve the miracle of modern medicine
13th April 2021 - News analysis |
Could cannabinoids, including CBD, provide a partial solution to the growing danger of diseases becoming resistant to existing antibiotics?
Could cannabinoids help in the fight against drug-resistant bacteria?
12th April 2021 - News analysis |
Scientific findings on the antimicrobial properties of cannabis – and in particular cannabinoids – have raised the question of whether they might play a role in combatting antibiotic-resistant bacteria such as MRSA
FTC-targeted company remains defiant, sees administrative fine as a victory
26th March 2021 - News analysis |
The CEO of one company targeted by the US Federal Trade Commission (FTC) in the first ever group of fines handed down by the government agency to CBD companies considers the event to be a David and Goliath victory of sorts
ValidCare reports to US FDA that trials find no evidence of CBD liver toxicity
23rd March 2021 - News analysis |
No evidence of liver toxicity from CBD has been found in the ValidCare study, the results of which have been given to the US Food and Drug Administration (FDA) for review
PG/phytol research should come with a health warning – lab rats are not humans
19th March 2021 - News analysis |
Any conclusion drawn from studies on rodents must be treated with caution if we want to know about effects on humans
Pregnant mice study touches on FDA questions, but more research is needed
12th March 2021 - News analysis |
The US Food and Drug Administration (FDA) has called for an exploration of the effects of CBD on certain vulnerable populations such as children and pregnant women as part of its consumer update
Jazz Pharmaceuticals buys Epidiolex manufacturer GW Pharma for $7.2bn
3rd February 2021 - News analysis |
GW Pharmaceuticals, the British manufacturer of the CBD-based epilepsy drug Epidiolex, has been acquired by Jazz Pharmaceuticals in a cash and shares deal worth over $7bn
Financial investments suggest a mood of optimism around CBD and cannabis
26th January 2021 - News analysis |
Renewed interest in financing of CBD and cannabis businesses could signal that investors are starting to be positive again about the future after companies seemingly weathered the worst of the storm in 2020
Dutch health ministry provides relief for UK patients forgotten in Brexit deal
25th January 2021 - News analysis |
Dutch officials have granted a six-month reprieve to find a solution to an omission in the Brexit negotiations that threatens to deprive British epilepsy patients of access to cannabis-based medicines
